NCT06000683: Empower-LCS

Empowering Patients' Lung Cancer Screening Uptake

Completed NA Results posted Last updated 20 February 2026

What this trial tests

NA trial testing Patient education in Lung Cancer in 79 participants. Completed in 25 November 2025.

Timeline

13 October 2023

Primary endpoint
21 March 2025

25 November 2025

Quick facts

Lead sponsor	University of California, Irvine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	79
Start date	13 October 2023
Primary completion	21 March 2025
Estimated completion	25 November 2025
Sites	7 locations across United States

Drugs / interventions tested

• Patient education — full drug profile →
• Referral to financial navigation resources
• Patient Reminders
• Provider Reminers

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →

Sponsor

University of California, Irvine

Who can join

Adults 50 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Order of LDCT Primary · within 6 months of enrollment

Number of participants who were ordered screening with Low Dose Computed Tomographyorder (LDCT) within 6 months after enrollment, assessed with self-reported surveys or EMR data extraction.

Group	Value	95% CI
Patient Participants	50

Receipt of LDCT Secondary · Within 6 months of enrollment

Number of participants who were completed screening with Low Dose Computed Tomographyorder (LDCT) within 6 months after enrollment, assessed with self-reported surveys or EMR data extraction.

Group	Value	95% CI
Empower LCS	17

LCS Discussion Secondary · within 6 months after enrollment

Number of participants who had a discussion about screening with Low Dose Computed Tomographyorder (LDCT) with their primary care provider measured within 6 months after enrollment, through self-reported surveys or EMR documentation of discussion in the primary care notes.

Group	Value	95% CI
Empower LCS	43

Perceived Risk of Lung Cancer Secondary · At 6 months post-enrollment

3-item validated survey questions (from Carter Harris et al) assessing patients' perceived risk of lung cancer. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 3-15. Higher score= higher perceived risk of lung cancer.

Group	Value	95% CI
Empower LCS	10.1	± 3

Perceived Severity of Lung Cancer Secondary · At 6 months post-enrollment

5-item validated survey questions assessing patients' perceived severity of lung cancer. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 5-25. Higher score= higher perceived severity of lung cancer.

Group	Value	95% CI
Empower LCS	18.1	± 3.1

Perceived Benefit of Lung Cancer Screening Secondary · At 6 months post-enrollment

6-item validated survey questions (from Carter Harris et al) assessing patients' perceived benefits of lung cancer screening. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 6-30. Higher score= higher perceived benefits of lung cancer screening.

Group	Value	95% CI
Empower LCS	24.7	± 4.7

Perceived Barriers to Lung Cancer Screening Secondary · At 6 months post-enrollment

19-item validated survey questions (from Carter Harris et al) assessing patients' perceived barriers to lung cancer screening. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 19-95. Higher score= higher perceived barriers to lung cancer screening.

Group	Value	95% CI
Empower LCS	37.5	± 15.6

Perceived Self-efficacy for Lung Cancer Screening Secondary · At 6 months post-enrollment

10-item validated survey questions (from Carter Harris et al) assessing patients' perceived self-efficacy to undergo lung cancer screening. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 5-50. Higher score= higher perceived self-efficacy.

Group	Value	95% CI
Empower LCS	41.7	± 7.5

Knowledge About Lung Cancer and Screening Secondary · At 6 months post-enrollment

Knowledge of lung cancer and LCS was assessed using 8-items validated questions (from Volk et al), and scored by awarding one point per correct answer selected and one point per incorrect answer not selected. The total score was calculated as sum of all points. Total score ranged between 0 to 8. Higher score= higher knowledge.

Group	Value	95% CI
Empower LCS	2.7	± 1.6

Providers' Perceived Barriers to Lung Cancer Screening Secondary · Baseline

9-item survey questions assessing providers' perceived barriers to lung cancer screening. Item responses use 5-point Likert scale. Total scores are calculated by summing item responses. Score is ranging between 9-45. Higher score= higher perceived barriers to lung cancer screening.

Group	Value	95% CI
Primary Care Providers	24.1	± 4.2

Patient and Provider Experience With Intervention Secondary · At the end of all study enrollments a subgroup of patients and providers were interviewed

Patient and Providers were asked questions about their experience with intervention components. Outcomes

Shared Positive Views of Current Lung Cancer Screening Protocols (e.g., timely, accessible)

Group	Value	95% CI
Empower LCS	4
Primary Care Providers	2

Shared Negative Views of Current Lung Cancer Screening Protocols (e.g., unnecessary, repetitive)

Group	Value	95% CI
Empower LCS	3
Primary Care Providers	4

Identified Barriers to Lung Cancer Screening

Group	Value	95% CI
Empower LCS	6
Primary Care Providers	5

Shared Impact of Intervention

Group	Value	95% CI
Empower LCS	8
Primary Care Providers	5

Provided Suggestions for Future Trials

Group	Value	95% CI
Empower LCS	8
Primary Care Providers	4

Sponsor's own description

Lung cancer is the leading cause of cancer related mortality. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases mortality rate of lung cancer by 20%. Yet many patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test the effect of a a multi-level intervention on ordering LDCT within 6 months after patient enrollment. Our proposed intervention includes (1) Primary care provider notifications of patients' LCS eligibility; (2) patients' education ; (3) patients' referral to financial navigation resources; and (4) patients' reminder to discuss LCS during PCP visit.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Reliability of Electronic Medical Record to Assess Patient's Eligibility for Lung Cancer Screening: Analysis of Two Pilot Trials.
   Sabour R, Bharucha M, Gandhi R, Echeverria R, et al · · 2025 · cited 1× · PMID 41338703 · DOI 10.1016/j.jacr.2025.10.020
2. Patients' and Providers' Perspective of a Multi-level Approach to Improve Participation in Low-dose CT for Lung Cancer Screening (Empower LCS): A Mixed-Methods Analysis.
   Sharifian M, Hoyt MA, Madan A, Lee S, et al · · 2026 · PMID 41904093 · DOI 10.1016/j.acra.2026.03.014
3. A Multilevel Approach to Improve Participation in Low-Dose CT for Lung Cancer Screening (Empower LCS): A Single-Arm Pilot Feasibility Clinical Trial.
   Shojazadeh A, Kao R, Pham T, Madan A, et al · · 2026 · PMID 41241060 · DOI 10.1016/j.jacr.2025.11.005